477 related articles for article (PubMed ID: 29344292)
1. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.
Suthahar N; Meijers WC; Silljé HHW; Ho JE; Liu FT; de Boer RA
Theranostics; 2018; 8(3):593-609. PubMed ID: 29344292
[TBL] [Abstract][Full Text] [Related]
2. The role of galectin-3 in heart failure and cardiovascular disease.
Zhong X; Qian X; Chen G; Song X
Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):197-203. PubMed ID: 30372548
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 in diabetic patients.
Pugliese G; Iacobini C; Ricci C; Blasetti Fantauzzi C; Menini S
Clin Chem Lab Med; 2014 Oct; 52(10):1413-23. PubMed ID: 24940712
[TBL] [Abstract][Full Text] [Related]
4. Galectin-3 Is a Potential Mediator for Atherosclerosis.
Gao Z; Liu Z; Wang R; Zheng Y; Li H; Yang L
J Immunol Res; 2020; 2020():5284728. PubMed ID: 32149158
[TBL] [Abstract][Full Text] [Related]
5. [Impact of galectin 3 as myofibrosis marker in clinical cardiology].
Málek F
Vnitr Lek; 2014 Apr; 60(4):327-30. PubMed ID: 24985993
[TBL] [Abstract][Full Text] [Related]
6. Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression.
Song X; Qian X; Shen M; Jiang R; Wagner MB; Ding G; Chen G; Shen B
Biochim Biophys Acta; 2015 Feb; 1853(2):513-21. PubMed ID: 25489662
[TBL] [Abstract][Full Text] [Related]
7. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis.
Yu L; Ruifrok WP; Meissner M; Bos EM; van Goor H; Sanjabi B; van der Harst P; Pitt B; Goldstein IJ; Koerts JA; van Veldhuisen DJ; Bank RA; van Gilst WH; Silljé HH; de Boer RA
Circ Heart Fail; 2013 Jan; 6(1):107-17. PubMed ID: 23230309
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice.
MacKinnon AC; Liu X; Hadoke PW; Miller MR; Newby DE; Sethi T
Glycobiology; 2013 Jun; 23(6):654-63. PubMed ID: 23426722
[TBL] [Abstract][Full Text] [Related]
9. The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases.
Sygitowicz G; Maciejak-Jastrzębska A; Sitkiewicz D
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053194
[TBL] [Abstract][Full Text] [Related]
10. Using galectin-3 to reduce heart failure rehospitalization.
Xue Y; Maisel A; Peacock WF
Future Cardiol; 2014 Mar; 10(2):221-7. PubMed ID: 24762249
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3 as a novel biotarget in cardiovascular alterations associated to development of severe aortic stenosis.
Arrieta V; Sádaba JR; Álvarez V; Rodríguez JA; López-Andrés N
An Sist Sanit Navar; 2019 Aug; 42(2):199-208. PubMed ID: 31317953
[TBL] [Abstract][Full Text] [Related]
12. Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing.
Carrasco-Sánchez FJ; Páez-Rubio MI
Mol Diagn Ther; 2014 Dec; 18(6):599-604. PubMed ID: 24989720
[TBL] [Abstract][Full Text] [Related]
13. Galectin-3 in Heart Failure: An Update of the Last 3 Years.
Gehlken C; Suthahar N; Meijers WC; de Boer RA
Heart Fail Clin; 2018 Jan; 14(1):75-92. PubMed ID: 29153203
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of galectin-3 in patients with heart failure.
Bošnjak I; Selthofer-Relatić K; Včev A
Dis Markers; 2015; 2015():690205. PubMed ID: 25960597
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 in heart failure with preserved ejection fraction.
de Boer RA; Edelmann F; Cohen-Solal A; Mamas MA; Maisel A; Pieske B
Eur J Heart Fail; 2013 Oct; 15(10):1095-101. PubMed ID: 23650131
[TBL] [Abstract][Full Text] [Related]
16. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.
Calvier L; Martinez-Martinez E; Miana M; Cachofeiro V; Rousseau E; Sádaba JR; Zannad F; Rossignol P; López-Andrés N
JACC Heart Fail; 2015 Jan; 3(1):59-67. PubMed ID: 25458174
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3 in Renal Pathology: More Than Just an Innocent Bystander.
Desmedt V; Desmedt S; Delanghe JR; Speeckaert R; Speeckaert MM
Am J Nephrol; 2016; 43(5):305-17. PubMed ID: 27166158
[TBL] [Abstract][Full Text] [Related]
18. Role of oxidative stress-related biomarkers in heart failure: galectin 3, α1-antitrypsin and LOX-1: new therapeutic perspective?
Lubrano V; Balzan S
Mol Cell Biochem; 2020 Jan; 464(1-2):143-152. PubMed ID: 31782085
[TBL] [Abstract][Full Text] [Related]
19. Analogs of tetrahydroisoquinoline natural products that inhibit cell migration and target galectin-3 outside of its carbohydrate-binding site.
Kahsai AW; Cui J; Kaniskan HU; Garner PP; Fenteany G
J Biol Chem; 2008 Sep; 283(36):24534-45. PubMed ID: 18556657
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3: an open-ended story.
Dumic J; Dabelic S; Flögel M
Biochim Biophys Acta; 2006 Apr; 1760(4):616-35. PubMed ID: 16478649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
